Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group (2-arm), Randomised, Double-blind, 12-week Trial to Explore the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Women Diagnosed With Vulvar Lichen Sclerosus (VLS)

Next Previous
Trial Profile

A Parallel Group (2-arm), Randomised, Double-blind, 12-week Trial to Explore the Efficacy and Safety of MC2-25 Cream and MC2-25 Vehicle in Women Diagnosed With Vulvar Lichen Sclerosus (VLS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MC2-25 (Primary) ; MC2-25 (Primary)
  • Indications Hyperkeratosis; Sclerosis; Vulvar lichen sclerosus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Orchid 1
  • Sponsors MC2 Therapeutics

Most Recent Events

  • 20 Nov 2024 Status changed from recruiting to completed.
  • 18 Jun 2024 Planned End Date changed from 10 Jun 2024 to 10 Nov 2024.
  • 18 Jun 2024 Planned primary completion date changed from 27 May 2024 to 10 Nov 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top